Depression

Depressed patients showed improvement with Lexapro

Published in Drug Week, June 11th, 2004

Forest Laboratories, Inc., (FRX) announced the results of a clinical study, which found that Lexapro (escitalopram oxalate) is a beneficial and well-tolerated treatment for depressed patients who failed to respond to initial antidepressant therapy with any one of four other selective serotonin reuptake inhibitors (SSRIs).

In addition, 60% of patients who were switched to Lexapro responded and more than 40% achieved remission of depressive symptoms after failing initial antidepressant therapy. The findings were presented at the 157th annual meeting of the American Psychiatric Association in New York.

"Forty percent of patients achieving remission from...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2004-06-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry